Loading...

Joseph Ma

TitleProfessor Of Clinical
InstitutionUniversity of California San Diego
DepartmentSchool of Pharmacy and Pharmaceutical Science
Address9500 Gilman Drive #0714
La Jolla CA 92093
Phone858-822-3485
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS, Nafziger AN, Ma J. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. J Clin Pharmacol. 2018 Apr 17. PMID: 29663428.
      View in: PubMed
    2. Ma J, El-Jawahri AR, LeBlanc TW, Roeland EJ. Pain Syndromes and Management in Adult Hematopoietic Stem Cell Transplantation. Hematol Oncol Clin North Am. 2018 Jun; 32(3):551-567. PMID: 29729788.
      View in: PubMed
    3. Wang WS, Ma J, Nelson SH, Revta C, Buckholz GT, Mulroney C, Roeland EJ. Transfusion practices at end of life for hematopoietic stem cell transplant patients. Support Care Cancer. 2018 Jun; 26(6):1927-1931. PMID: 29285557.
      View in: PubMed
    4. Wang WS, Ma J, Nelson SH, Revta C, Buckholz GT, Mulroney CM, Roeland EJ. Advance Care Planning and Palliative Care Integration for Patients Undergoing Hematopoietic Stem-Cell Transplantation. J Oncol Pract. 2017 Sep; 13(9):e721-e728. PMID: 28644706.
      View in: PubMed
    5. Bruggeman AR, Kamal AH, LeBlanc TW, Ma J, Baracos VE, Roeland EJ. Cancer Cachexia: Beyond Weight Loss. J Oncol Pract. 2016 Nov; 12(11):1163-1171. PMID: 27858548.
      View in: PubMed
    6. Roeland EJ, Ma J, Nelson SH, Seibert T, Heavey S, Revta C, Gallivan A, Baracos VE. Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. Support Care Cancer. 2017 02; 25(2):365-369. PMID: 27628947.
      View in: PubMed
    7. Kronenberg DG, Hagmann CH, Ma J, Revta C, Armstrong J, Roeland EJ. The Default Dilemma: Code Status Regardless of Medical Context. J Palliat Med. 2016 Nov; 19(11):1134. PMID: 27500355.
      View in: PubMed
    8. Momper JD, Tsunoda SM, Ma J. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans. J Clin Pharmacol. 2016 07; 56 Suppl 7:S82-98. PMID: 27385182.
      View in: PubMed
    9. Chang AT, Bertino JS, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma J. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction. Ther Drug Monit. 2016 06; 38(3):383-7. PMID: 26818625.
      View in: PubMed
    10. Ma J, Benn M, Nelson SH, Campillo A, Heavey SF, Cramer A, Revta C, Thornberry K, Roeland EJ. Exploring the Definition of an Informed Health Care Proxy. J Palliat Med. 2016 Mar; 19(3):250-1. PMID: 26836962.
      View in: PubMed
    11. Lam LH, Pirrello RD, Ma J. A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management. J Clin Pharmacol. 2016 07; 56(7):785-93. PMID: 26626053.
      View in: PubMed
    12. Ma J, Tran V, Chan C, Mitchell WM, Atayee RS. Retrospective analysis of pharmacist interventions in an ambulatory palliative care practice. J Oncol Pharm Pract. 2016 Dec; 22(6):757-765. PMID: 26428283.
      View in: PubMed
    13. Chang A, Roeland EJ, Atayee RS, Revta C, Ma J. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. J Pain Palliat Care Pharmacother. 2015 Sep; 29(3):247-60. PMID: 26368648.
      View in: PubMed
    14. Lin KJ, Ching A, Edmonds KP, Roeland EJ, Revta C, Ma J, Atayee RS. Variable Patterns of Continuous Morphine Infusions at End of Life. J Palliat Med. 2015 Sep; 18(9):786-9. PMID: 26107143; PMCID: PMC4553381.
    15. Langley-DeGroot M, Ma J, Hirst J, Roeland EJ. Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature. J Pain Palliat Care Pharmacother. 2015 Jun; 29(2):148-52. PMID: 26095486.
      View in: PubMed
    16. Masters JC, Harano DM, Greenberg HE, Tsunoda SM, Jang IJ, Ma J. Limited sampling strategy of partial area under the concentration-time curves to estimate midazolam systemic clearance for cytochrome P450 3A phenotyping. Ther Drug Monit. 2015 Feb; 37(1):84-9. PMID: 25004135; PMCID: PMC4282980.
    17. Bruggeman AR, Heavey SF, Ma J, Revta C, Roeland EJ. Lack of documentation of evidence-based prognostication in cancer patients by inpatient palliative care consultants. J Palliat Med. 2015 Apr; 18(4):382-5. PMID: 25608220.
      View in: PubMed
    18. Lee KC, Hudmon KS, Ma J, Kuo GM. Evaluation of a shared pharmacogenomics curriculum for pharmacy students. Pharmacogenomics. 2015; 16(4):315-22. PMID: 25823780.
      View in: PubMed
    19. Elder NM, Atayee RS, Best BM, Ma J. Response to urine drug testing for oxycodone and its metabolites as a tool for drug-drug interactions. J Anal Toxicol. 2015 Jan-Feb; 39(1):80. PMID: 25288719.
      View in: PubMed
    20. Elder NM, Atayee RS, Best BM, Ma J. Authors' reply. J Anal Toxicol. 2014 Sep; 38(7):463. PMID: 24986838.
      View in: PubMed
    21. Jiang JY, Best BM, Morello CM, Atayee RS, Ma J. Evaluation of concomitant methylphenidate and opioid use in patients with pain. J Anal Toxicol. 2014 Sep; 38(7):421-6. PMID: 24907143.
      View in: PubMed
    22. Barakat NH, Atayee RS, Best BM, Ma J. Urinary hydrocodone and metabolite distributions in pain patients. J Anal Toxicol. 2014 Sep; 38(7):404-9. PMID: 24836897.
      View in: PubMed
    23. Mann LM, Atayee RS, Best BM, Morello CM, Ma J. Urine specimen detection of zolpidem use in patients with pain. J Anal Toxicol. 2014 Jul-Aug; 38(6):322-6. PMID: 24802157.
      View in: PubMed
    24. Cao JM, Ma J, Morello CM, Atayee RS, Best BM. Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: comparison with urine. J Opioid Manag. 2014 May-Jun; 10(3):177-86. PMID: 24944068.
      View in: PubMed
    25. Ramey K, Ma J, Best BM, Atayee RS, Morello CM. Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug; 38(6):368-74. PMID: 24782142.
      View in: PubMed
    26. Ma J, Heavey SF, Revta C, Roeland EJ. Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther. 2014 Aug; 14(8):1113-20. PMID: 24707881.
      View in: PubMed
    27. Liu JC, Ma J, Morello CM, Atayee RS, Best BM. Naltrexone metabolism and concomitant drug concentrations in chronic pain patients. J Anal Toxicol. 2014 May; 38(4):212-7. PMID: 24659754.
      View in: PubMed
    28. Yee DA, Hughes MM, Guo AY, Barakat NH, Tse SA, Ma J, Best BM, Atayee RS. Observation of improved adherence with frequent urine drug testing in patients with pain. J Opioid Manag. 2014 Mar-Apr; 10(2):111-8. PMID: 24715666.
      View in: PubMed
    29. Elder NM, Atayee RS, Best BM, Ma J. Observations of urinary oxycodone and metabolite distributions in pain patients. J Anal Toxicol. 2014 Apr; 38(3):129-34. PMID: 24523296.
      View in: PubMed
    30. Luk S, Atayee RS, Ma J, Best BM. Urinary diazepam metabolite distribution in a chronic pain population. J Anal Toxicol. 2014 Apr; 38(3):135-42. PMID: 24500275.
      View in: PubMed
    31. Tse SA, Atayee RS, Ma J, Best BM. Factors affecting carisoprodol metabolism in pain patients using urinary excretion data. J Anal Toxicol. 2014 Apr; 38(3):122-8. PMID: 24488112.
      View in: PubMed
    32. Ma J, Horton JM, Hwang M, Atayee RS, Roeland EJ. A single-center, retrospective analysis evaluating the utilization of the opioid risk tool in opioid-treated cancer patients. J Pain Palliat Care Pharmacother. 2014 Mar; 28(1):4-9. PMID: 24417217.
      View in: PubMed
    33. Yee DA, Atayee RS, Best BM, Ma J. Observations on the urine metabolic profile of codeine in pain patients. J Anal Toxicol. 2014 Mar; 38(2):86-91. PMID: 24396053.
      View in: PubMed
    34. Moy KV, Ma J, Morello CM, Atayee RS, Best BM. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine. J Opioid Manag. 2014 Jan-Feb; 10(1):47-56. PMID: 24604569.
      View in: PubMed
    35. Bordson SJ, Atayee RS, Ma J, Best BM. Tricyclic antidepressants: is your patient taking them? Observations on adherence and unreported use using prescriber-reported medication lists and urine drug testing. Pain Med. 2014 Mar; 15(3):355-63. PMID: 24308804.
      View in: PubMed
    36. Ma J, Nafziger AN, Bertino JS. Endogenous 4ß-hydroxycholesterol-to-cholesterol ratio is not a validated biomarker for the assessment of CYP3A activity. Drug Metab Dispos. 2013 Nov; 41(11):1972. PMID: 24131962.
      View in: PubMed
    37. Moy KV, Ma J, Best BM, Atayee RS. Factors impacting variability of the urinary normeperidine-to-meperidine metabolic ratio in patients with chronic pain. J Anal Toxicol. 2014 Jan-Feb; 38(1):1-7. PMID: 24133175.
      View in: PubMed
    38. Guo AY, Ma J, Best BM, Atayee RS. Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine. J Anal Toxicol. 2013 Nov-Dec; 37(9):636-41. PMID: 24080973.
      View in: PubMed
    39. Ma J, Lee KC, Kuo GM. A massive open online course on pharmacogenomics: not just disruptive innovation but a possible solution. Pharmacogenomics. 2013 Jul; 14(10):1125-7. PMID: 23859565.
      View in: PubMed
    40. Kuo GM, Lee KC, Ma J. Implementation and outcomes of a live continuing education program on pharmacogenomics. Pharmacogenomics. 2013 Jun; 14(8):885-95. PMID: 23746183.
      View in: PubMed
    41. Tai W, Gong SL, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Stoch SA, Ma J. Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping. Drug Metabol Drug Interact. 2013; 28(4):217-23. PMID: 24114901.
      View in: PubMed
    42. Lee KC, Ma J, Hudmon KS, Kuo GM. A train-the-trainer approach to a shared pharmacogenomics curriculum for US colleges and schools of pharmacy. Am J Pharm Educ. 2012 Dec 12; 76(10):193. PMID: 23275658; PMCID: PMC3530055.
    43. Ma J, Nafziger AN, Bertino JS. Validating phenotyping cocktails: more work needs to be done. J Clin Pharmacol. 2012 Nov; 52(11):1772-3; author reply 1774-5. PMID: 23105127.
      View in: PubMed
    44. Nguyen AN, Hoffman JT, Tsunoda SM, Jang IJ, Ma J. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int J Clin Pharmacol Ther. 2012 Jul; 50(7):468-75. PMID: 22541751.
      View in: PubMed
    45. Ma J, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J Pharm Pract. 2012 Aug; 25(4):417-27. PMID: 22689709.
      View in: PubMed
    46. Wu JC, Nafziger AN, Bertino JS, Ma J. Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity. Drug Metab Lett. 2012 Jun 01; 6(2):94-101. PMID: 22594566.
      View in: PubMed
    47. Hansen PR, Ma J, Atayee RS. Preliminary analysis of midlevel practitioners on pain and health-related quality of life and function for a palliative care service at a comprehensive cancer center. J Palliat Med. 2012 Apr; 15(4):388-9. PMID: 22500477.
      View in: PubMed
    48. Nangia JR, Ma J, Nguyen CM, Mendes MA, Trivedi MV. Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther. 2012 Apr; 12(4):491-501. PMID: 22348344.
      View in: PubMed
    49. Lawson EB, Wu JC, Baldwin RM, Ingelman-Sundberg M, Rosenborg S, Yim DS, Yin OQ, Capparelli EV, Ma J. Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. Eur J Clin Pharmacol. 2012 Apr; 68(4):407-13. PMID: 22009190.
      View in: PubMed
    50. Nguyen CM, Mendes MA, Ma J. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Curr. 2011 May 15; 3:RRN1236. PMID: 21593964; PMCID: PMC3094768.
    51. Kuo GM, Ma J, Lee KC, Halpert JR, Bourne PE, Ganiats TG, Taylor P. Institutional Profile: University of California San Diego Pharmacogenomics Education Program (PharmGenEd™): bridging the gap between science and practice. Pharmacogenomics. 2011 Feb; 12(2):149-53. PMID: 21332308.
      View in: PubMed
    52. Nguyen CM, Mendes M, Tsunoda S, Ma J. Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. PLoS Curr. 2011 Jan 08; 3:RRN1207. PMID: 21278901; PMCID: PMC3024597.
    53. Ma J, Lee KC, Kuo GM. HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr. 2010 Dec 07; 2:RRN1203. PMID: 21151380; PMCID: PMC3000684.
    54. Wu JC, Beale KK, Ma J. Evaluation of current and upcoming therapies in oral mucositis prevention. Future Oncol. 2010 Nov; 6(11):1751-70. PMID: 21142661.
      View in: PubMed
    55. Ma J, Tsunoda SM, Bertino JS, Trivedi M, Beale KK, Nafziger AN. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010 Apr; 49(4):223-37. PMID: 20214407.
      View in: PubMed
    56. Lee KC, Ma J, Kuo GM. Pharmacogenomics: bridging the gap between science and practice. J Am Pharm Assoc (2003). 2010 Jan-Feb; 50(1):e1-14; quiz e15-7. PMID: 20368146.
      View in: PubMed
    57. Ma J, Nafziger AN, Mylott W, Haughey DB, Rocci ML, Bertino JS. Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping. Br J Clin Pharmacol. 2009 Mar; 67(3):374-5. PMID: 19220276; PMCID: PMC2675050.
    58. Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma J. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. Future Oncol. 2008 Aug; 4(4):483-500. PMID: 18684060.
      View in: PubMed
    59. Ma J, Nafziger AN, Mylott W, Haughey DB, Rocci ML, Bertino JS. Quantitative assessment of hepatic blood flow using intravenous indocyanine green. Eur J Clin Pharmacol. 2008 Nov; 64(11):1133-4. PMID: 18594801.
      View in: PubMed
    60. Ma J, Nafziger AN, Villano SA, Gaedigk A, Bertino JS. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob Agents Chemother. 2006 Apr; 50(4):1130-5. PMID: 16569820; PMCID: PMC1426970.
    61. Ma J, Nafziger AN, Rhodes G, Liu S, Bertino JS. Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab Dispos. 2006 May; 34(5):783-5. PMID: 16467135.
      View in: PubMed
    62. Ma J, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J Clin Pharmacol. 2006 Jan; 46(1):103-8. PMID: 16397289.
      View in: PubMed
    63. Ma J, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol. 2004 Jun; 44(6):570-6. PMID: 15145963.
      View in: PubMed
    64. Ma J, Nafziger AN, Bertino JS. Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers. J Clin Pharmacol. 2004 May; 44(5):447-56. PMID: 15102864.
      View in: PubMed
    Joseph's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _